(PDF) P1.01-90 a Pilot Trial Assessing Apatinib Combined

P1.01-90 a Pilot Trial Assessing Apatinib Combined With Docetaxel (DTX) as Second-Line Chemotherapy for EGFR Negative Advanced NSCLC)

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.646

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Apatinib Treatment Combined With Chemotherapy for Advanced Epithelial Ovarian Cancer: A Case Report

OncoTargets and Therapy

English

Mitomycin C and Vinorelbine for Second-Line Chemotherapy in NSCLC – A Phase II Trial

British Journal of Cancer

Cancer Research

English

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P066 a Phase I Study of Apatinib Combined With Pemetrexed and Carboplatin in Untreated EGFR-Negative Stage IV Non-Squamous NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Journal of Thoracic Oncology

Respiratory Medicine

English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy

Gastroenterology

English